ME/CFS Individualized Regimen Engine™
- Aug 27, 2025
- 21 min read
A Terrain-Aware Modeling Framework for Personalized Neuroimmune Stabilization in ME/CFS
By: Cynthia Adinig
Executive Summary
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) remains one of the most therapeutically fragmented conditions in modern medicine despite decades of biomedical evidence demonstrating profound neuroimmune, autonomic, mitochondrial, endocrine, inflammatory, and metabolic dysfunction (Institute of Medicine, 2015; Komaroff and Bateman, 2023). Patients frequently cycle through disconnected interventions, contradictory advice, repetitive therapeutic failures, and destabilizing treatment escalations without any unified system capable of interpreting how therapies interact with individual terrain state, post-exertional malaise (PEM), autonomic instability, mast-cell amplification, environmental triggers, hormonal fluctuation, or relapse-sensitive physiology.
Traditional treatment models often assume that patients with the same diagnosis should respond similarly to the same intervention strategy. In practice, this assumption repeatedly fails in ME/CFS populations. A patient with viral-reactivation dominance, severe orthostatic intolerance, and inflammatory PEM may require an entirely different therapeutic sequence than a patient with MCAS-sensitive terrain, endocrine instability, sensory overload, or predominantly mitochondrial impairment. Without phenotype-aware interpretation, interventions may appear inconsistent, poorly tolerated, or ineffective despite meaningful biologic rationale.
The CYNAERA ME/CFS Individualized Regimen Engine™ was developed as a terrain-aware educational modeling framework designed to simulate phased stabilization, therapeutic sequencing, flare-sensitive escalation, and longitudinal treatment personalization across heterogeneous ME/CFS populations. Rather than functioning as a static treatment protocol, the system models how patient state, symptom timing, autonomic behavior, inflammatory volatility, environmental burden, PEM delay, hormonal cycling, and recovery architecture may influence therapeutic tolerability and response across time.
The framework integrates logic from multiple CYNAERA systems, including:
ME/CFS Treatment Archetypes™
PHAROS™ + REWIRE™
Composite Diagnostic Fingerprints™ (CDF-ME™)
SymCas™ flare modeling
Pathos™ severity architecture
VitalGuard™ environmental overlays
XR/CR Pharmacology Doctrine™
Path of Remission™ staging logic
Together, these systems create a longitudinal infrastructure connecting diagnosis, phenotyping, flare prediction, therapeutic sequencing, environmental interpretation, and stabilization-aware intervention design. Importantly, this public-facing version remains intentionally abbreviated. The paper outlines core phases, sample logic structures, phenotype categories, and educational therapeutic scaffolding without exposing proprietary weighting systems, escalation matrices, adaptive scoring engines, or internal AI decision architecture embedded within licensed CYNAERA models. The goal is not to replace clinical judgment or provide rigid prescriptive care. Instead, the framework demonstrates how individualized neuroimmune treatment architecture can be systematically modeled in diseases characterized by fluctuating physiology, delayed rebound behavior, and relapse-sensitive instability.
The broader implication is significant. ME/CFS treatment failure may often reflect systems failure rather than absence of therapeutic possibility. Static treatment plans, generalized escalation schedules, non-stratified trials, and symptom-only interpretation remain poorly aligned with the biologic complexity of neuroimmune disease. The CYNAERA Regimen Engine™ instead approaches treatment as an adaptive process in which therapeutic response is state-dependent, phenotype-dependent, timing-dependent, and terrain-dependent rather than diagnosis-dependent alone.
Why Individualized Regimen Modeling Matters
The Failure of Static Treatment Systems
ME/CFS treatment has historically been constrained by rigid therapeutic thinking. Patients are frequently offered the same small group of interventions regardless of onset type, PEM severity, autonomic instability, inflammatory burden, mast-cell activation, hormonal state, environmental sensitivity, or viral-reactivation behavior. This creates a major mismatch between disease biology and treatment architecture.
The problem becomes especially severe in relapse-sensitive conditions. A patient may tolerate an intervention during one terrain state yet destabilize dramatically during another. Heat exposure, poor sleep, menstrual cycling, wildfire smoke, mold burden, reinfection, travel stress, cognitive overload, autonomic collapse, or inflammatory rebound may all alter physiologic buffering capacity independently of the intervention itself. Static treatment systems rarely account for these variables despite their major impact on symptom volatility and treatment tolerability.
The CYNAERA model therefore interprets treatment planning as a longitudinal systems problem rather than a simple medication-selection problem. Instead of asking only “Which treatment should this patient try?”, the framework evaluates:
which phenotype is dominant
which instability pattern is active
which systems are interacting
which triggers are amplifying relapse
which recovery capacities remain impaired
which sequencing order minimizes flare risk
This distinction helps explain why many conventional treatment strategies produce inconsistent outcomes across seemingly similar patients.
State-Dependent Therapeutic Logic
A central principle underlying the Regimen Engine™ is that therapeutic response in ME/CFS is state-dependent rather than universally predictable. The same intervention may produce stabilization, no effect, or severe destabilization depending on:
PEM sensitivity
autonomic compensation
mast-cell activation state
inflammatory load
mitochondrial reserve
hormonal cycling
environmental burden
cumulative physiologic stress
For example, a patient experiencing active autonomic collapse and inflammatory rebound may not tolerate the same intervention that becomes beneficial once pacing stabilization, hydration support, sleep recovery, and mast-cell control improve. Similarly, aggressive escalation in a severely fragile patient may worsen PEM and autonomic volatility even when the underlying therapeutic concept is biologically sound.
The CYNAERA framework therefore prioritizes sequencing logic and stabilization-aware escalation over aggressive intervention stacking. Treatment becomes less about intensity and more about timing, terrain, and physiologic readiness.
Why ME/CFS Treatment Response Varies
Terrain Variable | Potential Treatment Impact |
PEM severity | Alters recovery tolerance |
Autonomic instability | Changes medication tolerability |
MCAS amplification | Increases hypersensitivity reactions |
Viral-reactivation burden | Sustains inflammatory relapse |
Hormonal cycling | Alters immune and autonomic behavior |
Environmental burden | Amplifies flare risk |
Sleep disruption | Reduces physiologic resilience |
Cognitive overload | Triggers neuroimmune rebound |
The Need for Adaptive Neuroimmune Infrastructure
Most conventional treatment models still operate as though disease progression is relatively stable and predictable. ME/CFS does not behave this way. Patients often experience relapsing-remitting trajectories involving delayed PEM, fluctuating autonomic instability, inflammatory rebound, sensory hypersensitivity, and environmental sensitivity that change across time and physiologic context (Institute of Medicine, 2015; Komaroff and Lipkin, 2021).
The CYNAERA Regimen Engine™ was designed specifically for this type of complexity. Rather than functioning as a rigid protocol, the framework acts as an adaptive interpretive layer capable of integrating longitudinal symptom behavior, environmental overlays, flare sequencing, and phenotype-specific stabilization logic into individualized therapeutic modeling. This approach aligns with a broader transition occurring across post-viral and neuroimmune medicine. Increasing evidence suggests that ME/CFS, Long COVID, dysautonomia, MCAS, connective tissue disorders, and related infection-associated chronic conditions share overlapping biologic pathways involving neuroimmune dysfunction, autonomic instability, inflammatory amplification, endothelial disruption, and relapse-sensitive physiology (Raj et al., 2020; Proal and VanElzakker, 2021).
The implication is clear: individualized treatment architecture may be necessary not only for ME/CFS, but for the broader future of neuroimmune precision medicine.
Stratification: Patient Profiles
Why Phenotyping Comes First
The Regimen Engine™ begins with phenotyping because ME/CFS is not a biologically uniform illness. Patients differ substantially in onset pattern, relapse timing, post-exertional malaise (PEM) severity, autonomic instability, inflammatory activity, mitochondrial resilience, mast-cell sensitivity, endocrine modulation, environmental vulnerability, and recovery capacity (Institute of Medicine, 2015; Komaroff and Lipkin, 2021; Bateman et al., 2021). Without stratification, treatment sequencing becomes inconsistent and therapeutic interpretation becomes unreliable because patients with different dominant disease drivers may be grouped into the same clinical pathway despite requiring substantially different stabilization logic.
This heterogeneity has major implications for both care and research. A patient whose dominant pattern involves viral-reactivation behavior may respond differently than a patient whose primary limitation is autonomic instability, mast-cell activation, mitochondrial impairment, or severe cognitive PEM. Similarly, pediatric and young adult patients may demonstrate different trajectories than older adults because school demands, hormonal transitions, connective tissue overlap, and developmental factors can interact with neuroimmune instability in ways that alter both progression and tolerability (Rowe et al., 2017; Jason et al., 2021). This is why the CYNAERA Regimen Engine™ treats phenotype identification as the first step in therapeutic modeling rather than an optional descriptive layer.
The public-facing framework simplifies patients into four broad archetypes, while the internal CYNAERA system models a much larger set of microprofiles across immune, mitochondrial, autonomic, neurocognitive, endocrine, and environmental axes. These profiles are not intended to function as rigid diagnostic boxes. Most patients overlap multiple phenotypes simultaneously and may shift between dominant instability patterns over time. The point is not to reduce patients to categories, but to make treatment sequencing, flare prevention, and response interpretation more biologically coherent.
Type A: Post-Viral Gradual Onset
Post-viral gradual-onset patients often report EBV, mononucleosis, influenza, COVID-19, or another infectious trigger followed by progressive deterioration over months or years. Early symptoms may include fatigue, exertional intolerance, flu-like relapse patterns, cognitive dysfunction, sleep instability, sensory sensitivity, gastrointestinal changes, or evolving orthostatic symptoms before the illness becomes more clearly recognizable as ME/CFS. This pathway is consistent with broader research linking post-infectious illness, viral persistence hypotheses, immune dysregulation, and Long COVID overlap with ME/CFS-like trajectories (Proal and VanElzakker, 2021; Komaroff and Lipkin, 2021; Yong, 2021).
Within the CYNAERA model, this subgroup is considered particularly vulnerable to immune-reactivation cycles, delayed inflammatory rebound, cumulative exertional deterioration, and gradual autonomic progression. Standard treatment models may miss these patients early because they may not present with dramatic collapse at onset. Instead, they often decline in stages, with each relapse lowering functional baseline. This makes early pacing, sleep stabilization, inflammatory tracking, and autonomic monitoring especially important.
Treatment sequencing for this group should prioritize stabilization before immune escalation. Patients may require careful evaluation for EBV, HHV-6, CMV, recurrent inflammatory flares, orthostatic intolerance, mitochondrial stress, and delayed PEM timing. The Regimen Engine™ therefore interprets this phenotype as a terrain that may benefit from immune-aware, mitochondria-aware, and autonomic-aware modeling rather than generalized fatigue management alone.
Type B: Sudden-Onset Crash
Sudden-onset patients frequently describe abrupt functional collapse following infection, surgery, vaccination, severe stress exposure, toxic exposure, or another major physiologic insult. PEM tends to be more immediately disabling, and patients may experience rapid onset of dysautonomia, sensory overload, sleep fragmentation, inflammatory volatility, cognitive dysfunction, and severe functional loss. This presentation aligns with ME/CFS literature emphasizing sudden post-infectious onset, post-exertional worsening, autonomic dysfunction, and relapse-sensitive trajectories as core clinical features (Institute of Medicine, 2015; Bateman et al., 2021; Davenport et al., 2019).
Within the CYNAERA framework, sudden-onset crash patients are treated as high-risk for aggressive destabilization if interventions are introduced too quickly. These patients may have limited physiologic buffering capacity and may deteriorate from appointment burden, cognitive exertion, medication changes, environmental exposure, or attempted rehabilitation. The clinical problem is not merely fatigue. It is impaired recovery architecture.
The Regimen Engine™ therefore places this subgroup in a high-priority stabilization pathway. Pacing protection, autonomic support, sleep stabilization, environmental trigger reduction, and flare-aware monitoring should usually come before escalation into more intensive therapeutic strategies. In this phenotype, rapid treatment stacking can create interpretive chaos because clinicians may be unable to distinguish medication intolerance from PEM, mast-cell activation, autonomic collapse, or inflammatory rebound.
Type C: Pediatric and Young Adult Phenotypes
Pediatric and young adult ME/CFS populations require distinct consideration because disease presentation may be misread as school avoidance, anxiety, deconditioning, behavioral change, or adolescent adjustment rather than neuroimmune illness. Young patients frequently present with orthostatic intolerance, headache, abdominal symptoms, sleep disturbance, cognitive fatigue, sensory sensitivity, joint hypermobility, school-triggered PEM, and fluctuating functional capacity (Rowe et al., 2017; Institute of Medicine, 2015). These symptoms may become especially difficult to interpret when academic demands, screen exposure, social expectations, sports pressure, and family-system dynamics are not integrated into clinical assessment.
CYNAERA’s Regimen Engine™ interprets pediatric and young adult patients through developmental terrain rather than adult-only treatment assumptions. A child who worsens after school may not be anxious about school. They may be experiencing cognitive PEM, orthostatic stress from upright sitting, sensory overload from lights and noise, or delayed inflammatory rebound after cumulative exertion. This distinction matters because inappropriate school pressure, forced exercise escalation, or delayed accommodation can worsen long-term function.
This subgroup often requires educational pacing, cognitive-load management, autonomic protection, school accommodation planning, family education, and careful monitoring for EDS, POTS, MCAS-like symptoms, migraine, sleep disruption, and endocrine transition effects. The goal is not simply symptom relief, but developmental preservation. Early stabilization may reduce long-term disability risk by preventing repeated crash cycles during critical periods of education, growth, and identity formation.
Type D: MCAS-Dominant Terrain
MCAS-dominant patients demonstrate prominent mast-cell-sensitive behavior involving histamine intolerance, flushing, airway reactivity, chemical sensitivity, food-triggered instability, seasonal worsening, migraine activation, swelling, temperature sensitivity, gastrointestinal reactivity, sensory amplification, and paradoxical medication responses. Mast-cell activation and mast-cell-like inflammatory reactivity are increasingly recognized across ME/CFS, Long COVID, dysautonomia, and other complex chronic illness populations, though they remain underrecognized in conventional care settings (Afrin, 2016; Theoharides et al., 2015; Afrin et al., 2017).
Within the CYNAERA framework, MCAS-sensitive terrain significantly changes treatment logic. These patients may react not only to the active compound, but also to fillers, dyes, preservatives, capsules, excipients, rapid titration schedules, temperature changes, environmental exposures, hormonal shifts, stress physiology, or cumulative inflammatory burden. A failed medication trial may therefore reflect exposure mismatch rather than true pharmacologic incompatibility.
This subgroup frequently requires slower escalation, one-variable-at-a-time sequencing, environmental stabilization, careful formulation review, antihistamine-aware support, and XR/CR pharmacology when appropriate. The Regimen Engine™ treats tolerability as state-dependent rather than fixed. A patient may fail an intervention during active mast-cell destabilization and later tolerate the same therapeutic category after stabilization, trigger reduction, or formulation adjustment. This is why CYNAERA’s Body First Trial Protocol™, SymCas™, VitalGuard™, and XR/CR Pharmacology Doctrine™ connect directly to this phenotype.
Regimen Construction Logic
Building Around Stability Instead of Intensity
One of the most important differences between the CYNAERA Regimen Engine™ and conventional treatment approaches is that the framework does not assume more aggressive intervention automatically produces better outcomes. In highly relapse-sensitive illnesses such as ME/CFS, rapid escalation may worsen post-exertional malaise (PEM), autonomic instability, inflammatory volatility, mast-cell activation, sleep disruption, and cognitive dysfunction even when the underlying therapy has biologic merit (Bateman et al., 2021; Institute of Medicine, 2015).
The framework therefore prioritizes stabilization sequencing over therapeutic intensity. Patients first move through foundational terrain assessment involving autonomic stability, hydration status, PEM severity, inflammatory behavior, environmental burden, sleep quality, hormonal state, sensory overload thresholds, and mast-cell-sensitive behavior before more complex interventions are layered. This creates a clearer interpretive environment where clinicians and patients can better distinguish meaningful therapeutic response from destabilization caused by cumulative physiologic stress.
This distinction is especially important because many ME/CFS patients enter treatment already physiologically overloaded. Travel, poor sleep, environmental triggers, cognitive strain, hormonal fluctuation, food intolerance, and repeated failed interventions may all lower buffering capacity before therapy even begins. Without accounting for these variables, treatment sequencing becomes biologically noisy and difficult to interpret.
Phase 1: Terrain Stabilization
The first stage of the Regimen Engine™ focuses on stabilization rather than direct disease modification. This phase aims to reduce major destabilizing inputs while improving physiologic resilience enough for the patient to tolerate future intervention layers more safely.
Stabilization priorities may include:
pacing optimization
hydration and electrolyte support
autonomic regulation
sleep stabilization
mast-cell trigger reduction
environmental protection
sensory-load management
nutritional consistency
For many patients, this phase alone may significantly reduce symptom volatility because the system is no longer operating in constant physiologic overdrive. The framework does not interpret stabilization as passive care. Instead, it is viewed as active biologic preparation for clearer longitudinal therapeutic interpretation.
Patients with severe PEM or autonomic fragility often require especially careful onboarding during this stage. Small adjustments may produce disproportionately large physiologic effects because recovery architecture is impaired. This is one reason the framework favors low-and-slow escalation, XR/CR pharmacology where appropriate, and one-variable-at-a-time sequencing in highly sensitive populations.
Stabilization Priorities Before Escalation
Stabilization Target | Why It Matters |
Pacing control | Reduces PEM amplification |
Hydration optimization | Improves autonomic buffering |
Sleep stabilization | Supports inflammatory recovery |
Mast-cell management | Lowers hypersensitivity burden |
Environmental reduction | Reduces flare noise |
Cognitive-load management | Limits neuroimmune rebound |
Hormonal awareness | Improves timing interpretation |
Phase 2: Foundational Therapeutic Layering
Once terrain stability improves, the framework begins introducing foundational therapies based on dominant phenotype behavior and treatment tolerability. This phase commonly includes mitochondrial support, autonomic stabilization, mast-cell-sensitive support, anti-inflammatory strategies, and foundational nutritional interventions.
Importantly, the Regimen Engine™ avoids introducing multiple destabilizing variables simultaneously whenever possible. Conventional medicine frequently escalates too many interventions at once, making it impossible to determine:
which therapy helped
which therapy harmed
whether worsening reflects PEM
whether environmental triggers contributed
whether mast-cell activation altered tolerability
whether hormonal fluctuation changed symptom expression
The CYNAERA model instead favors interpretive clarity over speed. Therapeutic sequencing is designed to preserve signal integrity so meaningful patterns become easier to identify longitudinally. The framework also recognizes that treatment goals differ substantially across patients. Some individuals prioritize reduction in PEM frequency, while others focus on cognitive endurance, orthostatic stability, inflammatory control, sensory tolerance, or relapse reduction. The Regimen Engine™ therefore evaluates progress multidimensionally rather than relying on a single symptom score.
Phase 3: Advanced and Targeted Interventions
Advanced interventions are introduced only after stabilization and foundational layering demonstrate sufficient tolerability. This stage may involve antiviral strategies, immune-modulating therapies, neuroinflammatory interventions, endothelial support, mitochondrial intensification, or more specialized phenotype-aware escalation. The framework emphasizes that advanced therapies frequently fail not because the intervention itself lacks value, but because they are introduced into unstable terrain without adequate physiologic preparation. A patient experiencing active PEM cycling, severe orthostatic collapse, MCAS amplification, poor sleep, or environmental overload may be unable to tolerate even biologically rational therapies safely.
This sequencing logic aligns closely with broader CYNAERA systems including:
Body First Trial Protocol™
XR/CR Pharmacology Doctrine™
SymCas™ flare modeling
VitalGuard™ environmental overlays
Path of Remission™ staging
Together, these systems help reduce destabilization while improving therapeutic interpretability across time.
PEM-Aware Therapeutic Interpretation
Why PEM Changes Everything
Post-exertional malaise remains one of the most defining and misunderstood features of ME/CFS. Unlike ordinary fatigue, PEM involves delayed physiologic worsening after physical, cognitive, emotional, sensory, orthostatic, or environmental stress. Symptoms may intensify 24–72 hours after the triggering event and can include inflammatory rebound, autonomic destabilization, cognitive collapse, pain escalation, flu-like symptoms, sleep disruption, and profound functional decline (Institute of Medicine, 2015; Davenport et al., 2019).
The delayed nature of PEM creates major treatment-interpretation problems. Patients may appear stable during an appointment or shortly after intervention initiation yet deteriorate substantially afterward. Conventional medicine often misses this delay because assessment windows are too short and symptom tracking remains too static. The CYNAERA framework therefore treats PEM as a central interpretive variable rather than simply another symptom category. Therapeutic success is evaluated partly by whether:
crash frequency decreases
recovery windows shorten
exertional tolerance improves
relapse severity declines
resilience under stress increases
rather than whether patients experience temporary stimulation or isolated symptom suppression alone.
Cognitive PEM and Sensory Overload
The framework also recognizes cognitive PEM and sensory-triggered relapse as biologically meaningful forms of exertional injury. Patients may deteriorate after:
prolonged screen exposure
emotionally intense conversation
multitasking
travel
bright lights
noise exposure
complex information processing
even in the absence of substantial physical activity.
This distinction is critical because many patients are incorrectly told they are “deconditioned” when the real issue involves impaired neuroimmune recovery after cognitive or sensory stress. The Regimen Engine™ therefore integrates cognitive pacing, sensory-load management, and neuroimmune stabilization into treatment planning rather than treating cognition separately from physiology.
Flare-Aware Escalation
PEM-sensitive patients often require slower escalation schedules than conventional pharmacology models assume. A dose increase tolerated physiologically may still trigger delayed relapse several days later once cumulative autonomic and inflammatory burden exceeds recovery capacity.
The framework therefore favors:
slower titration
delayed assessment windows
symptom sequencing interpretation
longitudinal flare tracking
one-variable-at-a-time escalation
particularly in severe or highly sensitive populations.
This is one reason the Regimen Engine™ integrates directly with SymCas™, which models delayed flare behavior and symptom sequencing across time rather than evaluating isolated symptom snapshots alone.
Environmental and Hormonal Integration
Environment as an Active Variable
Environmental burden plays a major role in symptom behavior across many ME/CFS populations yet remains largely absent from conventional treatment systems. Patients frequently report worsening during:
wildfire smoke exposure
poor air quality
mold exposure
humidity changes
barometric instability
extreme heat
seasonal allergens
chemical exposure
These environmental variables may amplify inflammatory signaling, mast-cell activation, migraine behavior, autonomic dysfunction, cognitive instability, PEM severity, and treatment intolerance (D’Amato et al., 2015; Brewer et al., 2013).
The CYNAERA framework therefore interprets environment as an active biologic variable rather than background noise. VitalGuard™ overlays help contextualize flare behavior longitudinally so treatment response is not interpreted in isolation from physiologic stress exposure.
Hormonal Terrain and Treatment Tolerability
Hormonal fluctuation also significantly alters treatment response in many ME/CFS populations. Menstrual cycling, luteal inflammatory shifts, perimenopause, menopause, postpartum transition, thyroid instability, and endocrine stress states may all influence:
mast-cell activation
autonomic behavior
inflammatory sensitivity
migraine activity
sleep quality
PEM thresholds
medication tolerability
The Regimen Engine™ therefore incorporates hormonal timing awareness into sequencing interpretation whenever possible. A therapy introduced during a hormonally destabilized window may appear poorly tolerated even if it becomes beneficial under more stable conditions.
This principle aligns closely with CYNAERA’s broader DAWN™ hormone-immune terrain modeling architecture and ongoing menopause-autoimmune stabilization work.
Clinical Trial and Precision Medicine Implications
Why Conventional Trials Miss Signal
Many ME/CFS trials continue operating under assumptions better suited for relatively stable diseases rather than relapse-sensitive neuroimmune illness. Heterogeneous patients are grouped together despite substantial differences in:
PEM severity
autonomic instability
inflammatory burden
MCAS overlap
endocrine modulation
environmental sensitivity
viral-reactivation behavior
This phenotype dilution may obscure meaningful therapeutic response even when biologically responsive subgroups exist. The Regimen Engine™ demonstrates how adaptive sequencing, stabilization-aware onboarding, phenotype-aware stratification, and longitudinal flare interpretation may improve signal detection while reducing false-negative interpretation.
Toward Adaptive Neuroimmune Medicine
The broader implication extends beyond ME/CFS alone. Increasing evidence suggests that Long COVID, dysautonomia, mast-cell activation syndrome, connective tissue disorders, and related infection-associated chronic conditions share overlapping systems biology involving neuroimmune instability, autonomic dysfunction, inflammatory amplification, endothelial disruption, and relapse-sensitive physiology (Raj et al., 2020; Proal and VanElzakker, 2021).
The CYNAERA Regimen Engine™ therefore represents not simply a treatment model for one disease, but an example of how adaptive neuroimmune precision medicine infrastructure may evolve more broadly in the future.
Prompt Templates for Research and Educational Modeling
Explore the IACC Twin GPT™
The following educational prompts demonstrate how the CYNAERA ME/CFS Individualized Regimen Engine™ can be used as a terrain-aware modeling framework for research exploration, phenotype interpretation, and neuroimmune treatment sequencing. These prompts are intended for educational and exploratory use only and do not replace clinical judgment, institutional oversight, or individualized medical care.
Prompt 1: Sudden-Onset ME/CFS Modeling
“You are a biomedical researcher studying ME/CFS. Apply the CYNAERA Regimen Engine™ framework to a sudden-onset case (Type B). Which phase is the patient most likely in, and which supportive interventions might be simulated next within a non-clinical research model? Consider PEM severity, autonomic instability, inflammatory rebound, and pacing sensitivity.”
Prompt 2: Pediatric ME/CFS + POTS Progression Mapping
“Using the CYNAERA Regimen Engine™, outline how a pediatric ME/CFS case with comorbid POTS (Type C) could progress through the Stabilization → Modulation → Mapping → Personalization phases. Highlight flare safeguards, orthostatic considerations, cognitive pacing, school-related stressors, and environmental stabilization strategies.”
Prompt 3: Complex Neuroimmune Terrain Interpretation
“You are reviewing a complex ME/CFS case. Apply the CYNAERA ME/CFS Individualized Regimen Engine™ as a modeling framework. Use the Stabilization, Modulation, Mapping, and Personalization phases as scaffolding. Integrate patient-reported data including PEM delay, HR variability, symptom persistence, antihistamine response, temperature fluctuation, sensory overload, and environmental triggers into your interpretation. Identify the patient’s likely terrain state, areas of relapse risk, stabilization priorities, and research-backed intervention categories worth consideration. All outputs are exploratory and defer to clinical judgment and institutional protocols.”
Learn More
Learn more about the IACC Twin GPT™ and broader CYNAERA neuroimmune modeling architecture in the dedicated deep-dive white paper exploring terrain-aware AI systems for infection associated chronic conditions.
Conclusion
ME/CFS treatment failure is often interpreted as evidence that effective intervention is impossible. The CYNAERA framework proposes a different interpretation. Many failures may instead reflect the mismatch between static treatment systems and dynamic neuroimmune disease behavior.
The ME/CFS Individualized Regimen Engine™ was developed to model treatment as a longitudinal, terrain-aware process rather than a fixed protocol. Therapeutic response is interpreted as state-dependent, phenotype-dependent, timing-dependent, and environment-dependent rather than universally predictable across all patients with the same diagnosis.
By integrating phenotyping, flare-aware interpretation, PEM sequencing, environmental overlays, hormonal timing, stabilization logic, and adaptive therapeutic layering, the framework aims to improve biologic clarity while reducing avoidable destabilization. This approach may help explain why some patients deteriorate under generalized treatment assumptions while others improve when sequencing, pacing, formulation, environment, and terrain state are carefully aligned.
The broader CYNAERA ecosystem, including SymCas™, VitalGuard™, PHAROS™ + REWIRE™, Pathos™, Composite Diagnostic Fingerprints™ (CDF™), XR/CR Pharmacology Doctrine™, and the Path of Remission™ framework, extends this logic into a larger precision-oriented architecture connecting diagnosis, treatment sequencing, flare prediction, trial optimization, and neuroimmune stabilization across ME/CFS and related infection-associated chronic conditions.
The future of ME/CFS treatment may therefore depend not only on discovering new therapies, but also on building smarter systems capable of interpreting how and when therapies should be deployed across biologically complex, relapse-sensitive populations.
Frequently Asked Questions (FAQ)
Why do ME/CFS patients tolerate the same treatment differently?
Treatment response is heavily influenced by terrain state. PEM severity, autonomic instability, mast-cell activation, environmental burden, hormonal fluctuation, inflammatory load, sleep quality, and cumulative physiologic stress may all alter tolerability and therapeutic response.
Why does CYNAERA prioritize stabilization first?
Highly unstable patients often cannot tolerate aggressive escalation safely. Stabilization improves interpretive clarity and may reduce flare amplification before more advanced therapies are introduced.
Why does the framework avoid rapid escalation?
Rapid escalation may trigger delayed PEM, inflammatory rebound, autonomic collapse, or mast-cell destabilization that appears several days after the intervention rather than immediately.
Why are environment and hormones included in treatment logic?
Wildfire smoke, mold, poor air quality, humidity shifts, menstrual cycling, menopause, and endocrine fluctuation may significantly alter inflammatory signaling, autonomic stability, and treatment tolerability.
Does the Regimen Engine™ replace clinicians?
No. The framework functions as an educational and interpretive systems layer designed to support individualized reasoning, therapeutic sequencing, and longitudinal stabilization modeling.
Can this framework apply to Long COVID?
Yes. Many Long COVID populations demonstrate overlapping PEM, dysautonomia, neuroimmune instability, inflammatory amplification, mitochondrial dysfunction, and relapse-sensitive physiology similar to ME/CFS and related IACCs.
How to Cite This Paper
Adinig, C. (2026). ME/CFS Individualized Regimen Engine™. CYNAERA. Available at: https://www.cynaera.com/post/mecfs-individualized-engine
CYNAERA Framework Papers
This paper draws on a defined subset of CYNAERA Institute white papers that establish the methodological and analytical foundations of CYNAERA’s frameworks. These publications provide deeper context on prevalence reconstruction, remission, combination therapies and biomarker approaches. Our Long COVID Library, ME/CFS Library, Lyme Library, Autoimmune Library and CRISPR Remission Library are also in depth resources.
Author’s Note:
All insights, frameworks, and recommendations in this written material reflect the author's independent analysis and synthesis. References to researchers, clinicians, and advocacy organizations acknowledge their contributions to the field but do not imply endorsement of the specific frameworks, conclusions, or policy models proposed herein. This information is not medical guidance.
Patent-Pending Systems
Bioadaptive Systems Therapeutics™ (BST) and affiliated CYNAERA frameworks are protected under U.S. Provisional Patent Application No. 63/909,951. CYNAERA is built as modular intelligence infrastructure designed for licensing, integration, and strategic deployment across health, research, public sector, and enterprise environments.
Licensing and Integration
CYNAERA supports licensing of individual modules, bundled systems, and broader architecture layers. Current applications include research modernization, trial stabilization, diagnostic innovation, environmental forecasting, and population level modeling for complex chronic conditions. Basic licensing is available through CYNAERA Market, with additional pathways for pilot programs, institutional partnerships, and enterprise integration.
About the Author
Cynthia Adinig is the founder of CYNAERA, a modular intelligence infrastructure company that transforms fragmented real world data into predictive insight across healthcare, climate, and public sector risk environments. Her work sits at the intersection of AI infrastructure, federal policy, and complex health system modeling, with a focus on helping institutions detect hidden costs, anticipate service demand, and strengthen planning in high uncertainty environments.
Cynthia has contributed to federal health and data modernization efforts spanning HHS, NIH, CDC, FDA, AHRQ, and NASEM, and has worked with congressional offices including Senator Tim Kaine, Senator Ed Markey, Representative Don Beyer, and Representative Jack Bergman on legislative initiatives related to chronic illness surveillance, healthcare access, and data infrastructure. In 2025, she was appointed to advise the U.S. Department of Health and Human Services and has testified before Congress on healthcare data gaps and system level risk.
She is a PCORI Merit Reviewer, currently advises Selin Lab at UMass Chan, and has co-authored research with Harlan Krumholz, MD, Akiko Iwasaki, PhD, and David Putrino, PhD, including through Yale’s LISTEN Study. She also advised Amy Proal, PhD’s research group at Mount Sinai through its CoRE advisory board and has worked with Dr. Peter Rowe of Johns Hopkins on national education and outreach focused on post-viral and autonomic illness. Her CRISPR Remission™ abstract was presented at CRISPRMED26 and she has authored a Milken Institute essay on artificial intelligence and healthcare.
Cynthia has been covered by outlets including TIME, Bloomberg, Fortune, and USA Today for her policy, advocacy, and public health work. Her perspective on complex chronic conditions is also informed by lived experience, which sharpened her commitment to reforming how chronic illness is understood, studied, and treated. She also advocates for domestic violence prevention and patient safety, bringing a trauma informed lens to her research, systems design, and policy work. Based in Northern Virginia, she brings more than a decade of experience in strategy, narrative design, and systems thinking to the development of cross sector intelligence infrastructure designed to reduce uncertainty, improve resilience, and support institutional decision making at scale.
References
Afrin, L. B. (2016). Never Bet Against Occam: Mast Cell Activation Disease and the Modern Epidemics of Chronic Illness and Medical Complexity. Sisters Media.
Afrin, L. B., Self, S. and Menk, J. (2017). Characterization of mast cell activation syndrome. American Journal of the Medical Sciences, 353(3), pp. 207–215.
Bateman, L., Bested, A. C., Bonilla, H. F., Chheda, B. V., Chu, L., Curtin, J. M., Dempsey, T. T., Dimmock, M. E., Dowell, T. G., Jason, L. A., Klimas, N. G., Medow, M. S., Miwa, K., Rowe, P. C. and Vallings, R. (2021). ME/CFS: A Clinical Guide to Diagnosis and Management. Bateman Horne Center.
Brewer, J. H., Thrasher, J. D., Straus, D. C., Madison, R. A. and Hooper, D. (2013). Detection of mycotoxins in patients with chronic fatigue syndrome. Toxins, 5(4), pp. 605–617.
D’Amato, G., Vitale, C., Lanza, M., Molino, A., D’Amato, M. and Liccardi, G. (2015). Climate change, air pollution, and allergic respiratory diseases. Current Opinion in Allergy and Clinical Immunology, 16(5), pp. 434–440.
Davenport, T. E., Stevens, S. R., VanNess, J. M., Snell, C. R. and Little, T. (2019). Conceptual model for physical therapist management of chronic fatigue syndrome/myalgic encephalomyelitis. Physical Therapy, 90(4), pp. 602–614.
Esfandyarpour, R., Kashi, A., Nemat-Gorgani, M., Wilhelmy, J. and Davis, R. W. (2019). A nanoelectronics-blood-based diagnostic biomarker for myalgic encephalomyelitis/chronic fatigue syndrome. Proceedings of the National Academy of Sciences, 116(21), pp. 10250–10257.
Fluge, Ø., Mella, O., Bruland, O., Risa, K., Dyrstad, S. E., Alme, K., Rekeland, I. G., Sapkota, D., Røsland, G. V., Fosså, A., Lien, K., Herder, I., Bjøro, T., Salit, J., Viniski, S. and Kogelnik, A. (2016). Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome. JCI Insight, 1(21), e89376.
Hornig, M., Montoya, J. G., Klimas, N. G., Levine, S., Felsenstein, D., Bateman, L., Peterson, D. L., Gottschalk, C. G. and Lipkin, W. I. (2015). Distinct plasma immune signatures in ME/CFS are present early in the course of illness. Science Advances, 1(1), e1400121.
Institute of Medicine. (2015). Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. Washington, DC: National Academies Press.
Jason, L. A., Sunnquist, M., Brown, A., Reed, J., Taylor, R. R. and Evans, M. (2021). Examining case definition criteria for pediatric myalgic encephalomyelitis/chronic fatigue syndrome. Journal of Chronic Fatigue Syndrome, 29(2), pp. 112–126.
Komaroff, A. L. and Bateman, L. (2023). Advances in understanding the pathophysiology of myalgic encephalomyelitis/chronic fatigue syndrome. Nature Reviews Immunology, 23(5), pp. 327–340.
Komaroff, A. L. and Lipkin, W. I. (2021). Insights from myalgic encephalomyelitis/chronic fatigue syndrome may help unravel the pathogenesis of post-acute COVID-19 syndrome. Trends in Molecular Medicine, 27(9), pp. 895–906.
Loebel, M., Grabowski, P., Heidecke, H., Bauer, S., Hanitsch, L. G., Wittke, K., Meisel, C., Reinke, P., Volk, H. D., Fluge, Ø., Mella, O. and Scheibenbogen, C. (2014). Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with chronic fatigue syndrome. Brain, Behavior, and Immunity, 52, pp. 32–39.
Miller, A. H., Haroon, E., Raison, C. L. and Felger, J. C. (2014). Cytokine targets in the brain: Impact on neurotransmitters and neurocircuits. Depression and Anxiety, 31(4), pp. 297–306.
Nakatomi, Y., Mizuno, K., Ishii, A., Wada, Y., Tanaka, M., Tazawa, S., Onoe, K., Fukuda, S., Kawabe, J., Takahashi, K., Kataoka, Y., Shiomi, S., Yamaguti, K., Inaba, M., Kuratsune, H. and Watanabe, Y. (2014). Neuroinflammation in patients with chronic fatigue syndrome/myalgic encephalomyelitis: An 11C-(R)-PK11195 PET study. Journal of Nuclear Medicine, 55(6), pp. 945–950.
Naviaux, R. K., Naviaux, J. C., Li, K., Bright, A. T., Alaynick, W. A., Wang, L., Baxter, A., Nathan, N., Anderson, W. and Gordon, E. (2016). Metabolic features of chronic fatigue syndrome. Proceedings of the National Academy of Sciences, 113(37), pp. E5472–E5480.
Proal, A. D. and VanElzakker, M. B. (2021). Long COVID or post-acute sequelae of COVID-19 and ME/CFS. Frontiers in Microbiology, 12, 698169.
Raj, S. R., Arnold, A. C., Barboi, A., Claydon, V. E., Limberg, J. K., Lucci, V. M., Numan, M., Peltier, A., Snapper, H., Vernino, S. and Bourne, K. M. (2020). Long-COVID postural tachycardia syndrome: An American Autonomic Society statement. Clinical Autonomic Research, 31(3), pp. 365–368.
Rowe, P. C., Underhill, R. A., Friedman, K. J., Gurwitt, A., Medow, M. S., Schwartz, M. S., Speight, N., Stewart, J. M., Vallings, R. and Rowe, K. S. (2017). Myalgic encephalomyelitis/chronic fatigue syndrome diagnosis and management in young people: A primer. Frontiers in Pediatrics, 5, 121.
Systrom, D. M., McCall, T., Bernier, R., Lin, H., Croteau, D., Cracchiolo, M., Roselli, E. E. and Lorusso, J. R. (2022). Impaired systemic oxygen extraction long after mild COVID-19: Potential insight into post-exertional fatigue and exercise intolerance. Chest, 161(1), pp. 54–63.
Theoharides, T. C., Valent, P. and Akin, C. (2015). Mast cells, mastocytosis, and related disorders. New England Journal of Medicine, 373(2), pp. 1885–1886.
Tomas, C., Newton, J. and Watson, S. (2017). A review of hypothalamic-pituitary-adrenal axis function in chronic fatigue syndrome. ISRN Neuroscience, 2013, 784520.
Wirth, K. and Scheibenbogen, C. (2021). Pathophysiology of ME/CFS: Autoimmunity and autonomic dysfunction. Autoimmunity Reviews, 20(6), 102527.
Yong, S. J. (2021). Persistent brainstem dysfunction in Long COVID and ME/CFS: A hypothesis. Frontiers in Neurology, 12, 714166.
Younger, J., Noor, N., McCue, R. and Mackey, S. (2020). Low-dose naltrexone for chronic pain and neuroinflammation: Mechanisms and clinical implications. Clinical Rheumatology, 39(3), pp. 671–678.
Comments